By View North Holland [1].
Losing weight with a shot is nothing new anymore. The drug Ozempic itself became so popular in 2023 that there was a shortage for the target group for which it was intended, persons with diabetes. Overweight Netherlands is the first Dutch provider of the alternative Mounjaro, a drug that targets overweight and obese individuals and helps them lose 15% to 20% of their weight.
Following its success in the US and the Middle East, among others, waste medication Mounjaro is being introduced in the Netherlands. The active ingredient in the drug, Tirzepatide, causes the production of glucose-dependent insulinotropic polypeptide (GIP) to increase, thereby increasing insulin production and lowering blood sugar levels. Thus, a feeling of satiety during eating occurs earlier and is maintained longer. In addition, the drug affects the hormone glucagon-like peptide-1 (GLP-1), which results in reduced appetite in addition to regulating blood sugar.
Research shows that when patients inject themselves with the prescribed dose once a week for 12 months it leads to a 15% to 20% weight loss of their total body weight. Mounjaro is designed for overweight (BMI v. 27) and obese (BMI v. 30) individuals. In addition, it can be used by diabetic patients as an alternative to Ozempic.
Overweight Netherlands is the first Dutch provider of Mounjaro in the Netherlands and meanwhile the medication is being used by the first patients of the clinic in Amersfoort. Mounjaro is always used in combination with a program aimed at lifestyle changes, including guidance from a doctor, lifestyle coach, app and smart scale.
“The use of Mounjaro shows great results in reducing body weight. Thus, it represents a solution for individuals who cannot get there with lifestyle changes alone, but also do not want or cannot undergo surgery. The drug, in combination with an integral approach in which healthy habits are adopted, can ensure a healthy weight, including the benefits that come with it such as a reduced risk of cardiovascular disease,” said Edo Aarts, bariatric surgeon specializing in the guidance of overweight persons with weight loss and co-founder of Overgewicht Nederland. In total, Aarts has performed more than 2,000 gastric reductions, placed 2,000 gastric balloons and has extensive experience treating patients with weight loss injections. “We see the introduction of Mounjaro as a major breakthrough in the Dutch medical landscape. The drug delivers at least the same effects as existing drugs on the market. For example, like Ozempic, it not only reduces appetite but also increases insulin production. In addition, it is specifically designed for obese and overweight individuals. In doing so, it is a valuable addition to the market, also for the diabetes patients who depend on Ozempic.” , said Nick van Lanschot, CEO of Overweight Netherlands.
[1] (2024, Feb. 12). Overweight Netherlands first to bring obesity drug Mounjaro to Dutch market.
